Table 2.
Effect of K21 on HIV-associated Candida clinical strains.
| Candida n (%) | Fluconazole (FCZ) | K21 | ||||
|---|---|---|---|---|---|---|
| Mean MIC (SD) | MIC range (μg/ml) | MIC50 (μg/ml) | Mean MIC (SD) | MIC range (μg/ml) | MIC50 (μg/ml) | |
| FCZ-susceptible | ||||||
| C. albicans 6 (60%) | 0.52 (±0.28) | 0.12–1 | 0.5 | 46.86 (±17.11) | 31.24–62.48 | 62.48 |
| C. glabrata 2 (20.0%) | 0.50 (±0.00) | – | 0.5 | 31.24 (±0.00) | – | 31.24 |
| C. dubliniensis 2 (20.0%) | 0.26 (±0.33) | 0.03–0.5 | 0.5 | 62.48 (±0.00) | – | 62.48 |
| FCZ-resistant/intermediate | ||||||
| C. albicans 57 (91.9%) | 232.07 (±71.88) | 4–256 | 256 | 63.02 (±28.61) | 31.24–124.95 | 62.48 |
| C. glabrata 4 (6.5%) | 24.00 (±9.23) | 16–32 | 16 | 46.86 (±18.03) | 31.24–62.48 | 62.48 |
| C. dubliniensis 1 (1.6%) | 256 | – | – | 124.95 | – | – |